Richter Gedeon Vegyeszeti Gyar Rt

Maria Gazdag

Gabor Szepesi

Laszlo Szporny

Geza Takacsi Nagy

Lajos Kovacs

Eva Palosi

Csaba Szantay

Gyorgy Hajos

Bela Kiss

Tibor Keve

Bela Stefko

Bela Hegedus

Ferenc Trischler

Erik Bogsch

Zoltan Tuba

Laszlo Denes

Aniko Gere

Istvan Schon

Pal Vittay

Laszlo Nagy

Tibor Gizur

Gabor Megyeri

Attila Szemzo

Kalman Burger

Imre Peter

Maria Incze

Olga Nyeki

Jozsef Törley

Ferenc Soti

Geza Ivanyi

Gabor Tarkanyi

Anna Kassia Nee Zieger

Zsofia Papp Nee Sziklay

Zsuzsa Baloghne Kardos

Bobjak M Zsoldos

Eva E Kiss

Szikla Z Papp

Takacsi Nagy

Zsuzsanna Muck

Gizella Lorant

Iidiko Berhardt

Tamas Berhardt

Monika Babjak

The invention relates to N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine (nateglinide) in the novel crystalline form 'G' and a process for the preparation thereof. A process for the preparation of chirally pure nateglinide by treating a lower alkyl ester thereof with a base to yield an alkali salt and liberating the product from said salt by proper addition of an acid, is also provided. Still another aspect of the invention is a process for the preparation of nateglinide in the crystalline form 'H' from other crystalline modifications of nateglinide.

Process for the preparation of chirally pure N-(trans-4-is)

Biologically active eburnamenine derivatives, pharmaceutical

The invention relates to novel, parenterally useful, stable aqueous pharmaceutical compositions, mainly injectable solutions containing a bis-indole alkaloid. The compositions contain the zinc complex of a bis-indole alkaloid, preferably vincristine, vinblastine or 5'-nor-dihydrovinblastine together with a bivalent metal gluconate and a preserving agent dissolved in a mono- or polyhydric alcohol. The invention further relates to a process for the preparation of the above compositions. The composition according to the invention can be utilized for the parenteral administration of bis-indole alkaloids in the cancer chemotherapy.

Stable parenteral compositions of vinblastine or vincristine

The present invention relates to a process for the preparation of high purity crystalline peptides Arg Lys Asp hydrate acetate and Arg Lys Asp Val from crude, amorphous peptides Arg Lys Asp and Arg Lys Asp Val hydrate acetate. The process is characterized in that

High purity crystalline peptides arglysasp and arglysaspval and a

The invention relates to a novel process for the halogenation in 2-position of ergot alkaloids. The process is characterized by that as a halogenating agent a system consisting of dimethylsulfoxide, a trialkylhalosilane or triarylhalosilane and optionally a hydrogen halide is used.

Process for the preparation of 2-halogenated ergoline derivatives

The invention relates to new aqueous pharmaceutical compositions containing as active ingredient a pharmaceutically acceptable complex of a bis-indole compound with a bi- or multivalent metal ion in a therapeutically effective amount. The invention further relates to complexes formed between a bis-indole compound and a bi- or multivalent metal ion. According to another aspect of the invention there is provided a process for the preparation of a pharmaceutically acceptable metal complex of a bis-indole compound and optionally stable aqueous pharmaceutical compositions containing said metal complex, in which a solution of a bis-indole compound or a pharmaceutically acceptable salt thereof in an aqueous medium is reacted with a non-toxic water soluble salt of a bi- or multivalent metal capable of complexation, at a pH of 3.0 to 6.0, optionally in the presence of or followed by the addition of a conventional pharmaceutical carrier and/or further additive, or, if desired, the obtained complex is isolated. The aqueous pharmaceutical compositions according to the invention have substantially increased stability.

Metal complexes of bis-indole compounds and aqueous pharmaceutical

A parenteral solvent suitable for injectable solutions of eburnamenines and dihydroeburnamenines is disclosed, said solvent containing a buffer having the ability to buffer the injectable solutions at given pH values, at least one stabilizing agent which includes parenterally acceptable aliphatic alcohols containing one or more hydroxy groups or water-miscible ethers thereof, 30 to 70% by weight water and optional preservatives, anaesthetics, and antioxidants.

Parenteral solvent and a process for the preparation of stable solutions

Growing community of inventors

Budapest, Hungary

Maria Gazdag